MEK inhibitor can reverse the resistance to bevacizumab in A549 cells harboring Kirsten rat sarcoma oncogene homolog mutation

about

Targeting the KRAS Pathway in Non-Small Cell Lung Cancer.

P2860

Q38799845-3E106BA4-A4D1-4A03-88FA-DA03BA0D3048

P2860

MEK inhibitor can reverse the resistance to bevacizumab in A549 cells harboring Kirsten rat sarcoma oncogene homolog mutation

Item

http://www.wikidata.org/entity/Q36840372

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

MEK inhibitor can reverse the ...... coma oncogene homolog mutation

@en

type

Item

label

MEK inhibitor can reverse the ...... coma oncogene homolog mutation

@en

prefLabel

MEK inhibitor can reverse the ...... coma oncogene homolog mutation

@en

P1476

MEK inhibitor can reverse the ...... coma oncogene homolog mutation

@en

P2093

Hua Bai

http://www.w3.org/2001/XMLSchema#string

Jie Wang

http://www.w3.org/2001/XMLSchema#string

Ping Yan

http://www.w3.org/2001/XMLSchema#string

Xiaodan Yang

http://www.w3.org/2001/XMLSchema#string

Yaping Wang

http://www.w3.org/2001/XMLSchema#string

Yuan Wang

http://www.w3.org/2001/XMLSchema#string

Zhentao Liu

http://www.w3.org/2001/XMLSchema#string

Zhijie Wang

http://www.w3.org/2001/XMLSchema#string

Zhirong Shen

http://www.w3.org/2001/XMLSchema#string

P2860

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

What is the evidence that tumors are angiogenesis dependent?

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization.

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.

The shunt problem: control of functional shunting in normal and tumour vasculature.

P304

279-287

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/1759-7714.12325

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-12-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27148412

http://www.w3.org/2001/XMLSchema#string

P921

bevacizumab

P932

4846615

http://www.w3.org/2001/XMLSchema#string

MEK inhibitor can reverse the resistance to bevacizumab in A549 cells harboring Kirsten rat sarcoma oncogene homolog mutation

about

P2860

P2860

MEK inhibitor can reverse the resistance to bevacizumab in A549 cells harboring Kirsten rat sarcoma oncogene homolog mutation

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932